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Introduction
Th  e  inﬂ  ammatory myopathies – including dermatomyo-
sitis (DM), inclusion body myositis, and polymyositis 
(PM) – are poorly understood autoimmune diseases 
aﬀ  ect  ing skeletal muscle. Evidence regarding the signiﬁ  -
cance of type 1 interferons to these diseases, especially 
DM, is reviewed in the present article, with much of this 
material recently discussed elsewhere [1,2].
Th  e type 1 interferons are a class of molecules that 
include IFNα and IFNβ. After binding to the type 1 inter-
feron receptor (IFNAR) on target cells, these cytokines 
can stimulate the transcription of a set of genes, the type 1 
interferon-inducible genes. Proteins abundantly produced 
from these genes’ transcripts – such as myxovirus resis-
tance protein A, interferon-stimulated gene 15 (ISG15), 
and 2΄,5΄-oligoadenylate synthetase 1 – remain inside 
cells. Th  ey normally function as defenses against viral 
infections through a variety of means, such as inhibiting 
viral transcription, translation, or assembly of viral 
nucleocapsids. It is possible that the chronic intracellular 
overproduction of these transcripts and proteins might 
be directly harmful to cells, such as muscle ﬁ  bers  in 
myositis [3].
Myositis, pathology, and mechanisms
Th  e varied forms of myositis have distinct clinical and 
pathological features (Figure  1), and probably involve 
distinct mechanisms of tissue injury. DM, in addition to 
clinical skin involvement, has two unique pathological 
features (perifascicular atrophy and endothelial cell 
tubuloreticular inclusions) that distinguish it from other 
muscle diseases. Inclusion body myositis has a unique 
clinical distribution of involvement, with substantial 
weak  ness of the quadriceps and wrist and ﬁ  nger ﬂ  exors, 
as well as speciﬁ  c suggestive pathological features includ-
ing rimmed vacuoles. Th   e broad category of PM is mainly 
distinguished by a collection of otherwise individually 
non speciﬁ  c features. Although frequently lumped together, 
DM and PM probably involve entirely diﬀ  erent mecha-
nisms of tissue injury.
Because type 1 interferons may have many eﬀ  ects on 
cells of the immune system, they may have roles in the 
varied immune responses present across multiple myo-
sitis subtypes. Yet studies to date suggest that only in DM 
are these molecules strongly and directly inﬂ  uencing 
molecular events in muscle.
Why focus on type 1 interferons in 
dermatomyositis mechanism?
Recognition that cytokines are present in myositis muscle 
biopsy samples began with immunohistochemical studies 
for cytokine proteins [4]. Th   is approach is confounded by 
a number of technical and biological limitations [5], 
includ ing  nonspeciﬁ   c immunoreactivity, transient 
expres  sion of cytokines, and their low concentration. For 
these reasons, some investigators turned to examining 
cytokine mRNA transcripts in muscle homogenates [6]. 
Initial PCR-based studies of cytokine transcripts 
including IFNα and IFNγ generally found no myositis 
subtype-speciﬁ  c diﬀ  erences compared with nonmyositis 
muscle – except for granulocyte–macrophage colony-
stimulating factor, which was detected in 12 out of 15 
myositis samples but in none out of 10 controls [6]. Many 
subsequent studies of cytokine transcripts and proteins 
(discussed in [7-9]) have reported variable and often 
conﬂ  icting results.
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the low concentration of cytokines, downstream persist-
ing eﬀ  ects of cytokines have been sought. Two types of 
biomarkers (macromolecular and molecular) provide 
strong evidence that DM muscle has experienced strong 
signaling of the type 1 interferon receptor. More than 25 
years ago, tubuloreticular inclusions (also known as lupus 
inclusions) – macromolecular structures commonly visible 
with electron microscopy in DM muscle endothelial cells 
[10,11] and rarely seen in other forms of myositis – were 
recognized as downstream markers of type 1 interferon 
signaling. Tubuloreticular inclusions in circulating blood 
cells develop in patients treated with IFNα [12,13] and 
those in cultured endothelial cells and other cells develop 
directly in response to IFNα and IFNβ [14-16], but not 
IFNγ [13]. For uncertain reasons, no PubMed indexed 
publication made a connection between this tubulo-
reticular inclusion litera  ture and DM over 20 years [17].
Over the past 8 years the marked overproduction of type 
1 interferon-inducible transcripts and proteins in muscle 
has been found to be remarkably unique to DM in 
comparison with all other muscle diseases studied 
[2,18,19]. Microarray gene expression studies of muscle 
biopsy specimens measuring approximately 18,000 
transcripts in each of 113 muscle biopsy samples from 
patients with a wide range of myopathies showed that only 
DM samples with perifascicular atrophy have marked 
elevation of type 1 interferon-inducible trans  cripts (Figure 2a) 
[2]. In analyses combining publicly available data, the 
remarkable speciﬁ  city of these trans  cript abundances for 
DM is impressive. For example, the transcript for the type 
1 interferon-inducible gene ISG15 was higher in muscle in 
all 28 biopsies from adults with DM and perifascicular 
atrophy and from children with juvenile DM than in every 
one of 199 non-DM biopsy samples from a wide range of 
neuromuscular diseases (Figure 2b).
Two type 1 interferon-inducible proteins have similarly 
been shown to be highly speciﬁ   c biomarkers of DM 
muscle. Myxovirus resistance protein A is impressively 
and uniquely (in comparison with other muscle diseases) 
abundant in DM myoﬁ  bers with perifascicular atrophy 
and in DM capillaries (Figure 3) [18]. ISG15, a ubiquitin-
like modiﬁ   er, is furthermore attached to many other 
proteins in DM muscle, the identities of which have not 
been determined (Figure 2c). Exposure of human skeletal 
muscle cell cultures to IFNα or IFNβ produces a similar 
picture of ISG15 conjugation present in human DM 
samples (Figure 2c) [2].
DM is a systemic disease, involving muscle, skin, and, 
variably, other tissues. Skin gene expression proﬁ  ling, 
reported only in abstract format to date [20], has similarly 
shown marked abundance of type 1 interferon-inducible 
transcripts. Th   e topology of keratinocyte injury in DM skin 
is similar to that of myoﬁ  ber injury in DM muscle [21].
Figure 1. Diff  ering pathologies in myositis subtypes. The distribution of immune system cells diff  ers among myositis subtypes. (a) In 
dermatomyositis, immune system cells are predominantly in the regions of connective tissue that lie between muscle fascicles and include 
medium-sized and large blood vessels. In (b) inclusion body myositis and (c) polymyositis, immune cells surround myofi  bers. (d) Especially in 
inclusion body myositis, these may sometimes invade myofi  bers.
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signiﬁ  cant clinical evidence of muscle involvement have 
been classiﬁ   ed as clinically amyopathic DM. Auto-
antibodies to a classic type 1 interferon-inducible protein 
IFIH1 (inter  feron induced with helicase C domain; also 
called MDA-5) have been recently identiﬁ  ed [22]. Using 
optimized cutoﬀ   values in an ELISA assay, the presence 
of anti-IFIH1 antibodies in clinically amyopathic DM 
among 262 patients with a range of connective tissue 
diseases was 69% sensitive and 99.6% speciﬁ  c. Signiﬁ  cant 
anti-IFIH1 autoantibody levels were present in 22 out of 
32 patients with clinically amyopathic DM, but only in 
one of 35 patients with classic DM and in none of 53 
patients with PM. Th  ese remarkably strong data both 
indicate a clinically valuable biomarker of clinically 
amyopathic DM and provide mechanistic evidence for 
some abnormality related to type 1 interferons in 
clinically amyopathic DM. Th   e nature of this relationship 
is uncertain; one speculation is that IFIH1, a nuclear RNA 
helicase, is overproduced or altered in some way in 
Figure 2. Genomic identifi  cation of type 1 interferon-inducible pathway activation in dermatomyositis muscle. (a) Analysis of 22,283 
gene transcript probe sets (4,904 shown after fi  ltering; one per row) in 113 muscle biopsy samples (one per column) disclosed a cluster of type 1 
interferon-inducible genes specifi  cally and highly upregulated in dermatomyositis (DM) with perifascicular atrophy (PFA) (thin red stripe marked by 
an arrow). Enlargement of this arrowed region shown on the right. Red and green indicate high and low expression. IBM, inclusion body myositis; 
Myo, myopathies; PM, polymyositis. (b) High expression of transcripts for interferon-stimulated gene 15 (ISG15) and myxovirus resistance protein 
A (MxA) are extraordinarily specifi  c to DM muscle. JDM, juvenile DM. (c) Examples of ISG15 western blots show free ISG15 (approximately 15 kDa 
band) and multiple ISG15 conjugated proteins (discrete bands and smear shown at higher molecular weights) in DM but not other muscle biopsy 
samples. Cultured human skeletal muscle cells exposed to IFNβ develop the same pattern of free and conjugated ISG15 as occurs in DM. NoTx, no 
treatment. (d) MxA staining of DM muscle is sometimes so impressive that it is evident on glass slides viewed without the aid of a microscope. MxA 
is preferentially located in perifascicular myofi  bers and in blood vessel walls. Adapted from [2] with permission.
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response.
A blood type 1 interferon-inducible signature
Blood gene expression proﬁ   ling has also demonstrated 
marked abundance of these transcripts in patients with 
active DM, such as untreated patients, but also in PM (see 
below) [19]. One study that did not ﬁ  nd marked type 1 
interferon-inducible transcript abundance in DM blood 
samples had included almost only treated patients (11 out 
of 12 patients receiving prednisone; eight of these patients 
receiving an additional second immuno  sup  pressant agent) 
[23]. Microarray experiments measure the abundance of 
10,000s of transcripts simultaneously; any set of transcripts 
may be called a signature, but what is impressive about 
such experiments in DM and PM blood samples is the 
dominance of these gene expression patterns by type 1 
interferon-inducible genes. In a study of 23 patients with 
DM and PM, at least 24 of the highest expressed 25 genes 
among approximately 38,000 genes studied are all known 
to be highly inducible by type 1 interferons [19].
Th   e type 1 interferon-inducible transcript overproduc-
tion in DM and PM is highly correlated, within individual 
patients, with clinical measures of disease activity [19] 
(Figure 4 and unpublished data). Although the absolute 
magnitude of the upregulation of this signature does not 
highly correlate with disease severity across patients, 
within individual patients the signature does track 
disease activity – a situation similar to the commonly 
used clinical biomarker creatine kinase.
What drives the production of these downstream 
biomarkers of type 1 interferon signaling in DM 
muscle?
A fundamental question that has not been answered is 
what drives the production of type 1 interferon-inducible 
molecules in DM muscle. Speciﬁ   c elevation of type 1 
inter  feron transcripts or proteins has not been demon-
strated in DM muscle. Both microarray and real-time 
quantitative PCR do not show impressive diﬀ  er  ences, 
compared with other myositis samples, in transcripts 
encoding a range of IFNα subtypes or IFNβ in the same 
DM muscle samples that have marked upregulation 
(10-fold to 100-fold) of downstream type 1 interferon-
inducible transcripts (unpublished data). Immunoblots 
from myositis samples similarly do not appear to show 
diﬀ   erential presence of IFNα or IFNβ protein in DM 
muscle (preliminary unpublished data).
Th  is situation parallels that seen in systemic lupus 
erythematosus. Although studies performed almost 
30 years ago detected molecules believed to be IFNα in 
60 to 76% of systemic lupus erythematosus blood samples 
using functional antiviral assays sometimes in combina-
tion with neutralizing antibodies [24-27], the literature 
has been notable for the absence of detection of IFNα in 
systemic lupus erythematosus blood or tissue samples by 
direct methods such as ELISA, immunoblot, or mass 
spectrometry. For example, one study found measurable 
levels of IFNα protein by ELISA in only two out of 38 
patients, while most of these same 38 samples showed 
marked increases in type 1 interferon-inducible trans-
cripts [28]. Th   e lack of direct detection of IFNα protein 
has been attributed to potential technical limitations, 
although unexpected results in science have often been 
assumed to be erroneous. A more recent functional assay 
looking at type 1 interferon-inducible transcription has 
similarly detected activity in systemic lupus erythema-
tosus plasma [29].
Th   e interpretation of the results of functional assays is 
complicated by potential type 1 interferon autocrine 
mechanisms. In mouse cells, autostimulation of the 
IFNAR by early secreted type 1 interferons results in 
marked ampliﬁ  cation of IFNα production [30-33]. Anti-
IFNα antibodies used in functional assays to neutralize 
sample IFNα could potentially diminish type 1 inter  feron-
inducible gene transcription through neutralizing early 
secreted reporter cell IFNα, although this possibility is 
speculative.
For juvenile DM, the functional assay for gene trans-
cription has been used for detection of serum type 1 
interferon-inducing activity and similarly interpreted as 
indicating the presence of IFNα in some blood samples 
[34]. What is particularly remarkable about this study 
was the marked range of interferon-inducing activity of 
serum from healthy children and adults, which varies by 
over 100-fold and includes many healthy people whose 
activity exceeded the mean value for the juvenile DM 
population.
Th  ese data suggest that the marked production of 
type  1 interferon-inducible transcripts and proteins in 
Figure 3. Myxovirus resistance protein A expression in 
dermatomyositis muscle. Image of whole muscle section stained 
for myxovirus resistance protein A (MxA) showing abundant 
myofi  ber protein expression (brown) preferentially in a perifascicular 
distribution. Adapted from [3] with permission.
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sustained activation of the type 1 interferon receptor 
IFNAR in the absence of excessive (compared with the 
wide range of normal) type 1 interferons, or through 
mechanisms even further downstream that bypass 
IFNAR. Th  e most natural interpretation of the data to 
date suggests that what may turn out to be most crucial 
with regard to DM myoﬁ  ber injury is not the abundance 
of a type 1 interferon, but rather sustained abnormal 
function of the IFNAR or a further downstream process.
Potential role for type 1 interferons in polymyositis 
and inclusion body myositis
PM is an umbrella term for patients with various forms of 
myositis that are diﬃ   cult to classify. DM and PM have 
substantial diﬀ   erences with regard to abundance of 
type 1 interferon-inducible molecules in muscle biopsy 
samples (Figure 5), yet marked overexpression of type 1 
interferon-inducible genes has also been found in blood 
in PM [19]. Within PM muscle, inﬂ  ammatory  cells 
typically surround, displace, and sometimes invade muscle 
ﬁ  bers. Th   ese cells include T cells, myeloid dendritic cells, 
macrophages, and plasma cells (reviewed in [3]). Type 1 
interferons have multiple eﬀ  ects on these cell types, and 
it is possible that through these eﬀ   ects the type 1 
interferon system is contributing to PM myoﬁ  ber injury.
Patients with inclusion body myositis – a highly 
inﬂ  ammatory disorder of muscle, as judged by abundance 
of immune system cells and transcripts in muscle – do 
not have high levels of muscle or blood type 1 
interferon-inducible transcripts (Figure 5), although a 
small propor  tion of patients may have modest elevation 
of such transcripts in blood alone. As in PM, the 
mechanistic interpretation of blood expression of these 
transcripts is uncertain, and could reﬂ  ect  less-speciﬁ  c 
eﬀ  ects driving immune cell development.
Predicted exacerbations with TNFα inhibition
TNFα appears to have an antagonistic relationship with 
type 1 interferons [35]. It may directly inhibit the genera-
tion of plasmacytoid dendritic cells from progenitor cells 
and may inhibit plasmacytoid dendritic cell production 
of type 1 interferons. Studies of etanercept in Sjogren’s 
syndrome indeed showed that this drug increased type 1 
interferon activity [36]. Accordingly, models that propose 
a signiﬁ  cant role for type 1 interferons in the pathogenesis 
of myositis predict that TNFα inhibition might exacer-
bate myositis. Published experience with TNFα inhibition 
in patients with myositis appears to support this model. 
Two open-label studies of inﬂ  iximab have been termi-
nated before completion or had substantial dropout rates 
for reasons that included disease progression [37,38]. 
Although this class of drugs may prove useful in the 
management of some patients, currently it appears 
unlikely to be of more general use for myositis.
Conclusion: diagnostics and therapeutic 
development
Th  e presence of marked overproduction of type 1 
interferon-inducible transcripts in blood specimens from 
Figure 4. Blood type 1 interferon-inducible gene expression correlation with disease activity. Downregulation of six type 1 interferon-
inducible genes in eight patients, correlating with improvement in clinical disease from time point 1 (active) to time point 2 (improving). Adapted 
from [19] with permission.
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diagnostic use [19]. Th  ese biomarkers may be able to 
distinguish these disorders from inclusion body myositis 
and other muscle diseases that sometimes present diag-
nostic uncertainty. Furthermore, they may be useful for 
therapeutic development. A phase 1b trial of anti-IFNα 
therapy has been initiated in DM and PM [39]. Entry 
criteria into this study include the presence of suﬃ   ciently 
high type 1 interferon-inducible gene expression in blood. 
Future studies targeting the IFNAR or further down  stream 
events have strong rationale in DM, and perhaps in PM.
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